Transaortic Shallow Septal Myectomy and Cutting of Secondary Fibrotic Mitral Valve Chordae—A 5-Year Single-Center Experience in the Treatment of Hypertrophic Obstructive Cardiomyopathy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Research Design and Sample
2.2. Surgical Procedure
2.3. Statistical Analysis
3. Results
3.1. Patients’ Demographic and Preoperative Characteristics
3.2. Postoperative (Predischarge) Data
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Gersh, B.J.; Maron, B.J.; Bonow, R.O.; Dearani, J.A.; Fifer, M.A.; Link, M.S.; Naidu, S.S.; Nishimura, R.A.; Ommen, S.R.; Rakowski, H.; et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011, 124, 2761–2796. [Google Scholar] [CrossRef] [PubMed]
- Zamorano, J.L.; Anastasakis, A.; Borger, M.A.; Borggrefe, M.; Cecchi, F.; Charron, P.; Hagege, A.A.; Lafont, A.; Limongelli, G.; Mahrholdt, H.; et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 2014, 35, 2733–2779. [Google Scholar] [CrossRef]
- Maron, B.J. Clinical Course and Management of Hypertrophic Cardiomyopathy. N. Engl. J. Med. 2018, 379, 655–668. [Google Scholar] [CrossRef] [PubMed]
- Maron, B.J.; McKenna, W.J.; Danielson, G.K.; Kappenberger, L.J.; Kuhn, H.J.; Seidman, C.E.; Shah, P.M.; Spencer, W.H.; Spirito, P.; Ten Cate, F.J.; et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. J. Am. Coll. Cardiol. 2003, 42, 1687–1713. [Google Scholar] [CrossRef] [Green Version]
- Ferrazzi, P.; Spirito, P.; Iacovoni, A.; Calabrese, A.; Migliorati, K.; Simon, C.; Pentiricci, S.; Poggio, D.; Grillo, M.; Amigoni, P.; et al. Transaortic Chordal Cutting Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy with Mild Septal Hypertrophy. J. Am. Coll. Cardiol. 2015, 66, 1687–1696. [Google Scholar] [CrossRef] [Green Version]
- Ommen, S.R.; Nishimura, R.A. Hypertrophic cardiomyopathy-one case per year?: A clarion call to do what is right. JAMA Cardiol. 2016, 1, 333–334. [Google Scholar] [CrossRef] [Green Version]
- Iacovoni, A.; Spirito, P.; Simon, C.; Iascone, M.; Di Dedda, G.; De Filippo, P.; Pentiricci, S.; Boni, L.; Senni, M.; Gavazzi, A.; et al. A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur. Heart J. 2012, 33, 2080–2087. [Google Scholar] [CrossRef] [Green Version]
- Schoendube, F.A.; Klues, H.G.; Reith, S.; Flachskampf, F.A.; Hanrath, P.; Messmer, B.J. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 1995, 92, 122–127. [Google Scholar] [CrossRef]
- Ionilă, P.; Jurcuţ, R.; Ferariu, N.; Roşca, M.; Chivulescu, M.; Mursă, A.; Militaru, S.; Ionescu, A.A.; Căldăraru, C.; Fruntelată, A.G.; et al. Romanian Registry of Hypertrophic Cardiomyopathy—Overview of general characteristics and therapeutic choices at a national level. Rom. J. Intern. Med. 2018, 56, 203–209. [Google Scholar] [CrossRef] [Green Version]
- Micheu, M.M.; Popa-Fotea, N.-M.; Oprescu, N.; Bogdan, S.; Dan, M.; Deaconu, A.; Dorobantu, L.; Gheorghe-Fronea, O.; Greavu, M.; Iorgulescu, C.; et al. Yield of Rare Variants Detected by Targeted Next-Generation Sequencing in a Cohort of Romanian Index Patients with Hypertrophic Cardiomyopathy. Diagnostics 2020, 10, 1061. [Google Scholar] [CrossRef]
- Afanasyev, A.V.; Bogachev-Prokophiev, A.V.; Ovcharov, M.A.; Pivkin, A.N.; Zalesov, A.S.; Budagaev, S.A.; Sharifulin, R.M.; Zheleznev, S.I.; Karaskov, A.M. Single-Centre Experience of Surgical Myectomy for Hypertrophic Obstructive Cardiomyopathy. Heart Lung Circ. 2020, 29, 949–955. [Google Scholar] [CrossRef]
- Kharbanda, R.K.; Lodder, L.; Ragab, A.A.Y.; de Jong, P.L.; Kik, C.; Brundel, B.J.J.M.; Taverne, Y.J.H.J.; de Groot, N.M.S.; Bogers, A.J.J.C. Early and late post-operative arrhythmias after surgical myectomy: 45 years of follow-up. Int. J. Cardiol. 2021, 328, 63–68. [Google Scholar] [CrossRef] [PubMed]
- Lapenna, E.; Nisi, T.; Carino, D.; Bargagna, M.; Ruggeri, S.; Zancanaro, E.; Del Forno, B.; Schiavi, D.; Agricola, E.; Castiglioni, A.; et al. Hypertrophic cardiomyopathy with moderate septal thickness and mitral regurgitation: Long-term surgical results. Eur. J. Cardio-Thorac. Surg. 2021, 60, 244–251. [Google Scholar] [CrossRef] [PubMed]
- Pruna-Guillen, R.; Pereda, D.; Castellà, M.; Sandoval, E.; Affronti, A.; García-álvarez, A.; Perdomo, J.; Ibáñez, C.; Jordà, P.; Prat-González, S.; et al. Outcomes of septal myectomy beyond 65 years, with and without concomitant procedures. J. Clin. Med. 2021, 10, 3499. [Google Scholar] [CrossRef] [PubMed]
- Tang, B.; Song, Y.; Cui, H.; Ji, K.; Yu, Q.; Zhu, C.; Zhao, S.; Wang, S. Prognosis of adult obstructive hypertrophic cardiomyopathy patients with different morphological types after surgical myectomy. Eur. J. Cardio-Thorac. Surg. 2018, 54, 310–317. [Google Scholar] [CrossRef]
- Meng, X.; Liang, M.; Shi, Y.E.; Zhou, S.; Zhang, W.; Gao, C. Effects of surgical septal myectomy on survival in patients with hypertrophic obstructive cardiomyopathy. Anatol. J. Cardiol. 2020, 23, 342–348. [Google Scholar] [CrossRef]
- Yang, H.; Woo, A.; Monakier, D.; Jamorski, M.; Fedwick, K.; Wigle, E.D.; Rakowski, H. Enlarged left atrial volume in hypertrophic cardiomyopathy: A marker for disease severity. J. Am. Soc. Echocardiogr. 2005, 18, 1074–1082. [Google Scholar] [CrossRef]
- Falasconi, G.; Pannone, L.; Slavich, M.; Margonato, A.; Fragasso, G.; Spoladore, R. Atrial fibrillation in hypertrophic cardiomyopathy: Pathophysiology, diagnosis and management. Am. J. Cardiovasc. Dis. 2020, 10, 409. [Google Scholar]
- Nedios, S.; Dinov, B.; Seewöster, T.; Lindemann, F.; Richter, S.; Arya, A.; Dagres, N.; Husser, D.; Bollmann, A.; Hindricks, G.; et al. Characteristics of left atrial remodeling in patients with atrial fibrillation and hypertrophic cardiomyopathy in comparison to patients without hypertrophy. Sci. Rep. 2021, 11, 12411. [Google Scholar] [CrossRef]
- Olivotto, I.; Cecchi, F.; Casey, S.A.; Dolara, A.; Traverse, J.H.; Maron, B.J. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001, 104, 2517–2524. [Google Scholar] [CrossRef] [Green Version]
- Kubo, T.; Kitaoka, H.; Okawa, M.; Hirota, T.; Hayato, K.; Yamasaki, N.; Matsumura, Y.; Yabe, T.; Takata, J.; Doi, Y.L. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy—Results from Kochi RYOMA study. Circ. J. 2009, 73, 1599–1605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Velzen, H.G.; Theuns, D.A.M.J.; Yap, S.C.; Michels, M.; Schinkel, A.F.L. Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. Am. J. Cardiol. 2017, 119, 100–105. [Google Scholar] [CrossRef] [PubMed]
- Rowin, E.J.; Hausvater, A.; Link, M.S.; Abt, P.; Gionfriddo, W.; Wang, W.; Rastegar, H.; Estes, N.A.M.; Maron, M.S.; Maron, B.J. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 2017, 136, 2420–2436. [Google Scholar] [CrossRef] [PubMed]
- Olivotto, I.; Oreziak, A.; Barriales-Villa, R.; Abraham, T.P.; Masri, A.; Garcia-Pavia, P.; Saberi, S.; Lakdawala, N.K.; Wheeler, M.T.; Owens, A.; et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020, 396, 759–769. [Google Scholar] [CrossRef]
- Spertus, J.A.; Fine, J.T.; Elliott, P.; Ho, C.Y.; Olivotto, I.; Saberi, S.; Li, W.; Dolan, C.; Reaney, M.; Sehnert, A.J.; et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): Health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021, 397, 2467–2475. [Google Scholar] [CrossRef]
- Maron, B.J.; Maron, M.S. Hypertrophic cardiomyopathy. Lancet 2013, 381, 242–255. [Google Scholar] [CrossRef]
- Ommen, S.R.; Mital, S.; Burke, M.A.; Day, S.M.; Deswal, A.; Elliott, P.; Evanovich, L.L.; Hung, J.; Joglar, J.A.; Kantor, P.; et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2020, 76, 2467–2475. [Google Scholar] [CrossRef]
- Maron, B.J.; Desai, M.Y.; Nishimura, R.A.; Spirito, P.; Rakowski, H.; Towbin, J.A.; Dearani, J.A.; Rowin, E.J.; Maron, M.S.; Sherrid, M.V. Management of Hypertrophic Cardiomyopathy. J. Am. Coll. Cardiol. 2022, 79, 390–414. [Google Scholar] [CrossRef]
- Panaich, S.S.; Badheka, A.O.; Chothani, A.; Mehta, K.; Patel, N.J.; Deshmukh, A.; Singh, V.; Savani, G.T.; Arora, S.; Patel, N.; et al. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998–2010]). Am. J. Cardiol. 2014, 114, 1390–1395. [Google Scholar] [CrossRef]
- Kim, L.K.; Swaminathan, R.V.; Looser, P.; Minutello, R.M.; Wong, S.C.; Bergman, G.; Naidu, S.S.; Gade, C.L.F.; Charitakis, K.; Singh, H.S.; et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003–2011. JAMA Cardiol. 2016, 1, 324–332. [Google Scholar] [CrossRef] [Green Version]
- Östman-Smith, I.; Wettrell, G.; Keeton, B.; Holmgren, D.; Ergander, U.; Gould, S.; Bowker, C.; Verdicchio, M. Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur. Heart J. 2008, 29, 1160–1167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maron, B.J.; Rowin, E.J.; Casey, S.A.; Haas, T.S.; Chan, R.H.M.; Udelson, J.E.; Garberich, R.F.; Lesser, J.R.; Appelbaum, E.; Manning, W.J.; et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age. Circulation 2013, 127, 585–593. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maron, B.J.; Rowin, E.J.; Casey, S.A.; Link, M.S.; Lesser, J.R.; Chan, R.H.M.; Garberich, R.F.; Udelson, J.E.; Maron, M.S. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J. Am. Coll. Cardiol. 2015, 65, 1915–1928. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maron, B.J.; Dearani, J.A.; Ommen, S.R.; Maron, M.S.; Schaff, H.V.; Nishimura, R.A.; Ralph-Edwards, A.; Rakowski, H.; Sherrid, M.V.; Swistel, D.G.; et al. Low operative mortality achieved with surgical septal myectomy role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J. Am. Coll. Cardiol. 2015, 66, 1307–1308. [Google Scholar] [CrossRef] [Green Version]
- Maron, M.S.; Rowin, E.J.; Wessler, B.S.; Mooney, P.J.; Fatima, A.; Patel, P.; Koethe, B.C.; Romashko, M.; Link, M.S.; Maron, B.J. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients with Hypertrophic Cardiomyopathy. JAMA Cardiol. 2019, 4, 644–657. [Google Scholar] [CrossRef] [Green Version]
- Rowin, E.J.; Maron, B.J.; Carrick, R.T.; Patel, P.P.; Koethe, B.; Wells, S.; Maron, M.S. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J. Am. Coll. Cardiol. 2020, 75, 3033–3043. [Google Scholar] [CrossRef]
- Kotkar, K.D.; Said, S.M.; Dearani, J.A.; Schaff, H.V. Hypertrophic obstructive cardiomyopathy: The Mayo Clinic experience. Ann. Cardiothorac. Surg. 2017, 6, 329. [Google Scholar] [CrossRef] [Green Version]
- Woo, A.; Williams, W.G.; Choi, R.; Wigle, E.D.; Rozenblyum, E.; Fedwick, K.; Siu, S.; Ralph-Edwards, A.; Rakowski, H. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005, 111, 2033–2041. [Google Scholar] [CrossRef] [Green Version]
- Nguyen, A.; Schaff, H.V.; Sedeek, A.F.; Geske, J.B.; Dearani, J.A.; Ommen, S.R.; Lahr, B.D.; Viehman, J.K.; Nishimura, R.A. Septal Myectomy and Concomitant Coronary Artery Bypass Grafting for Patients With Hypertrophic Cardiomyopathy and Coronary Artery Disease. In Mayo Clinic Proceedings; Elsevier: Rochester, MN, USA, 2020; Volume 95, pp. 521–525. [Google Scholar] [CrossRef]
- Wehman, B.; Ghoreishi, M.; Foster, N.; Wang, L.; D’Ambra, M.N.; Maassel, N.; Maghami, S.; Quinn, R.; Dawood, M.; Fisher, S.; et al. Transmitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy. Ann. Thorac. Surg. 2018, 105, 1102–1108. [Google Scholar] [CrossRef] [Green Version]
- Varma, P.K.; Ahamed, H. Left Atrial Approach to Septal Myectomy: Word of Caution. Ann. Thorac. Surg. 2018, 106, 1591–1592. [Google Scholar] [CrossRef] [Green Version]
- Sherrid, M.V.; Balaram, S.; Kim, B.; Axel, L.; Swistel, D.G. The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy A Test in Context. J. Am. Coll. Cardiol. 2016, 67, 1846–1858. [Google Scholar] [CrossRef] [PubMed]
- Urbano-Moral, J.A.; Gutierrez-Garcia-Moreno, L.; Rodriguez-Palomares, J.F.; Matabuena-Gomez-Limon, J.; Niella, N.; Maldonado, G.; Valle-Racero, J.I.; Niella, M.; Teixido-Tura, G.; Garcia-Dorado, D.; et al. Structural abnormalities in hypertrophic cardiomyopathy beyond left ventricular hypertrophy by multimodality imaging evaluation. Echocardiography 2019, 36, 1241–1252. [Google Scholar] [CrossRef] [PubMed]
- Joseph, N.; Craft, M.; Mill, L.A.; Erickson, C.C.; Danford, D.A.; Kutty, S.; Li, L. Assessment of mitral valve function in children and young adults with hypertrophic cardiomyopathy using three-dimensional echocardiography. Int. J. Cardiol. 2021, 332, 182–188. [Google Scholar] [CrossRef] [PubMed]
- Lentz Carvalho, J.; Schaff, H.V.; Morris, C.S.; Nishimura, R.A.; Ommen, S.R.; Maleszewski, J.J.; Dearani, J.A. Anomalous papillary muscles—Implications in the surgical treatment of hypertrophic obstructive cardiomyopathy. J. Thorac. Cardiovasc. Surg. 2022, 163, 83–89. [Google Scholar] [CrossRef] [PubMed]
- Polanco, A.R.; D’Angelo, A.; Shea, N.; Yu, S.N.; Chiang, Y.P.; Shimada, Y.; Weiner, S.D.; Takayama, H. Impact of Septal Myectomy Volume on Mitral-Valve Replacement Rate in Hypertrophic Cardiomyopathy Patients. Cardiology 2020, 145, 161–167. [Google Scholar] [CrossRef]
- Balaram, S.K.; Ross, R.E.; Sherrid, M.V.; Schwartz, G.S.; Hillel, Z.; Winson, G.; Swistel, D.G. Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy. Ann. Thorac. Surg. 2012, 94, 1990–1998. [Google Scholar] [CrossRef]
- Vriesendorp, P.A.; Schinkel, A.F.L.; Soliman, O.I.I.; Kofflard, M.J.M.; De Jong, P.L.; Van Herwerden, L.A.; Ten Cate, F.J.; Michels, M. Long-term benefit of myectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 2015, 115, 670–675. [Google Scholar] [CrossRef]
- Kwon, D.H.; Smedira, N.G.; Thamilarasan, M.; Lytle, B.W.; Lever, H.; Desai, M.Y. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. J. Thorac. Cardiovasc. Surg. 2010, 140, 317–324. [Google Scholar] [CrossRef] [Green Version]
- Bogachev-Prokophiev, A.; Afanasyev, A.; Zheleznev, S.; Fomenko, M.; Sharifulin, R.; Kretov, E.; Karaskov, A. Mitral valve repair or replacement in hypertrophic obstructive cardiomyopathy: A prospective randomized study. Interact. Cardiovasc. Thorac. Surg. 2017, 25, 356–362. [Google Scholar] [CrossRef] [Green Version]
- Afanasyev, A.V.; Bogachev-Prokophiev, A.V.; Zheleznev, S.I.; Sharifulin, R.M.; Zalesov, A.S.; Budagaev, S.A. Edge-to-Edge Repair Versus Secondary Cord Cutting During Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy: A Pilot Randomised Study. Heart Lung Circ. 2021, 30, 438–445. [Google Scholar] [CrossRef]
- Lapenna, E.; Nisi, T.; Ruggeri, S.; Trumello, C.; Del Forno, B.; Schiavi, D.; Meneghin, R.; Castiglioni, A.; Alfieri, O.; De Bonis, M. Edge-to-Edge Mitral Repair Associated With Septal Myectomy in Hypertrophic Obstructive Cardiomyopathy. In Proceedings of the Annals of Thoracic Surgery, Lisbon, Portugal, 3–5 October 2019; Elsevier: Rochester, MN, USA, 2020; Volume 110. [Google Scholar]
- Maron, B.J.; Dearani, J.A.; Maron, M.S.; Ommen, S.R.; Rastegar, H.; Nishimura, R.A.; Swistel, D.G.; Sherrid, M.V.; Ralph-Edwards, A.; Rakowski, H.; et al. Why we need more septal myectomy surgeons: An emerging recognition. J. Thorac. Cardiovasc. Surg. 2017, 154, 1681–1685. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Variable | Preoperative | Postoperative a | p-Value | |
---|---|---|---|---|
Hospital mortality | - | 1 (1.2%) | - | |
Iatrogenic septal defect | - | 0 | - | |
NYHA class III/IV | 49 (59%) | 0 | <0.0001 | |
Atrial fibrillation | 26 (31%) | 13 (16%) | <0.05 | |
Maximum septal thickness | 24 ± 6 mm | 16 ± 3 mm | <0.0001 | |
LV outflow gradient | 93 ± 33 mmHg | 13 ± 11 mmHg | <0.0001 | |
Mitral regurgitation grade | 0/1 | 12 (14%) | 52 (65%) | |
2 | 39 (47%) | 27 (34%) | ||
3/4 | 32 (39%) | 1 (1.2%) | <0.0001 | |
LV ejection fraction | 63 ± 5% | 59 ± 5% | <0.0001 | |
Mitral valve replacement | - | 2 (2.4%) | - | |
Mitral valve repair | - | 81 (97.6%) | - | |
Aortic valve repair | - | 4 (4.8%) | - | |
Aortic valve replacement | - | 2 (2.4%) | - | |
Tricuspid valve repair | - | 2 (2.4%) | - | |
Atrial septal defect closure | - | 2 (2.4%) | - | |
Pacemaker implantation | - | 8 (9.6%) | - | |
CABG | - | 9 (10.8%) | - |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dorobantu, L.F.; Iosifescu, T.A.; Ticulescu, R.; Greavu, M.; Alexandrescu, M.; Dermengiu, A.; Micheu, M.M.; Trofin, M. Transaortic Shallow Septal Myectomy and Cutting of Secondary Fibrotic Mitral Valve Chordae—A 5-Year Single-Center Experience in the Treatment of Hypertrophic Obstructive Cardiomyopathy. J. Clin. Med. 2022, 11, 3083. https://doi.org/10.3390/jcm11113083
Dorobantu LF, Iosifescu TA, Ticulescu R, Greavu M, Alexandrescu M, Dermengiu A, Micheu MM, Trofin M. Transaortic Shallow Septal Myectomy and Cutting of Secondary Fibrotic Mitral Valve Chordae—A 5-Year Single-Center Experience in the Treatment of Hypertrophic Obstructive Cardiomyopathy. Journal of Clinical Medicine. 2022; 11(11):3083. https://doi.org/10.3390/jcm11113083
Chicago/Turabian StyleDorobantu, Lucian Florin, Toma Andrei Iosifescu, Razvan Ticulescu, Maria Greavu, Maria Alexandrescu, Andrei Dermengiu, Miruna Mihaela Micheu, and Monica Trofin. 2022. "Transaortic Shallow Septal Myectomy and Cutting of Secondary Fibrotic Mitral Valve Chordae—A 5-Year Single-Center Experience in the Treatment of Hypertrophic Obstructive Cardiomyopathy" Journal of Clinical Medicine 11, no. 11: 3083. https://doi.org/10.3390/jcm11113083
APA StyleDorobantu, L. F., Iosifescu, T. A., Ticulescu, R., Greavu, M., Alexandrescu, M., Dermengiu, A., Micheu, M. M., & Trofin, M. (2022). Transaortic Shallow Septal Myectomy and Cutting of Secondary Fibrotic Mitral Valve Chordae—A 5-Year Single-Center Experience in the Treatment of Hypertrophic Obstructive Cardiomyopathy. Journal of Clinical Medicine, 11(11), 3083. https://doi.org/10.3390/jcm11113083